Abstract:Cancer cells are characterized by aberrant signal transduction and cell cycle control pathways that lead to unchecked cell proliferation. Uncontrolled cancer cell proliferation, as well as immune suppressive macrophage proliferation, contribute to tumor growth and spread. Effort to suppress tumor cell growth using Inhibitors of PI3K or MEK signaling pathways can initially inhibit tumor growth, but resistance develops due to upregulation of the alternative pathway. We identified a novel series of allosteric tyrosine kinase receptor inhibitors that induce synthetic lethality in AML, lung carcinoma, pancreatic carcinoma, and other tumor cells and in proliferating macrophages in vitro and in vivo by simultaneously inhibiting cMyc and Tor and activating the stress activated kinase JNK, leading to p53 mediated cell cycle arrest. Select kinase inhibitors with a unique positioning of a single side chain inhibited CDK8/19 and thereby Myc while stimulating phosphorylation and activation of JNK and p38. JNK activation promoted sustained ATF-2 and cJun-mediated p53 and Chk1/Chk2 activation, thereby promoting cell cycle arrest in G2/M and ultimately, apoptosis. These inhibitors potently suppressed tumor growth in vivo by halting both tumor cell and macrophage proliferation in G2/M. They synergized with anti-PD-1 and anti-CTLA-4 and led to tumor eradication and immunological memory formation. These studies identify novel allosteric inhibitors with potent synthetically lethal anti-tumor activity. Citation Format: Hui Chen, Jason Rivera, Marc Paradise, Zihan Xu, Giuliana Mognol, Judith Varner. A new cancer therapy strategy: Synthetic lethality induced by inhibition of mTOR and cMYC and JNK activation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7577.

Enhancing oncogenic signaling to kill cancer cells

Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Paradoxical activation of oncogenic signaling as a cancer treatment strategy

Synthetic Enforcement of STING Signaling in Cancer Cells Appropriates the Immune Microenvironment for Checkpoint Inhibitor Therapy.

Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells

The case for therapeutic overactivation of oncogenic signaling as a potential cancer treatment strategy

Shifting the paradigm: engaging multicellular networks for cancer therapy

Targeting replication stress in cancer therapy

Drug Repurposing: Exploring Potential Anti-Cancer Strategies by Targeting Cancer Signalling Pathways

Interplay between Cell Death and Cell Proliferation Reveals New Strategies for Cancer Therapy

Replication Stress: A Review of Novel Targets to Enhance Radiosensitivity-From Bench to Clinic

Key signal transduction pathways and crosstalk in cancer: Biological and therapeutic opportunities

Exploiting cell death and tumor immunity in cancer therapy: challenges and future directions

Abstract 7577: A new cancer therapy strategy: Synthetic lethality induced by inhibition of mTOR and cMYC and JNK activation

Advancing cancer therapy: new frontiers in targeting DNA damage response

Overcoming Irinotecan Resistance by Targeting Its Downstream Signaling Pathways in Colon Cancer

A compact synthetic pathway rewires cancer signaling to therapeutic effector release

Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer

Targeting immunogenic cell stress and death for cancer therapy